Dasatinib
10 NDCs across 9 manufacturers|8 Generic,2 Brand
Dasatinib is used to treat lymphoid leukemia and myeloid leukemia, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on Jun 28, 2006, and the first generic was approved Jun 10, 2016. FDA's Orange Book lists 54 AB-rated (therapeutically equivalent) products for this ingredient. In 2024, Medicare Part D spent $569 million on Dasatinib across 44,000 claims for 7,778 beneficiaries.
Dasatinib is available as 10 NDCs from 9 manufacturers (8 generic, 2 brand), with NADAC prices from $26.46 to $591.18 per EA — the most expensive product costs about 22× the cheapest. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
10
8G / 2B
Manufacturers
9
competing in market
Price Spread
$26.46 – $591.18
per EA
7d Activity
avg +1.0% WoW · of 10 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
E.R. Squibb & Sons, L.L.C. manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Lead class
Kinase Inhibitor class view
See how this market rolls up into the broader therapeutic class and compare other drugs in the same bucket.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
9 manufacturers producing DASATINIB(1 pricing outlier)
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
SPRYCEL 100 MG TABLET | $591.1812 per EA | — |
SPRYCEL 50 MG TABLET | $327.4239 per EA | — |
DASATINIB 100 MG TABLET | $26.4568 per EA | +1.04% |
DASATINIB 100 MG TABLET | $26.4568 per EA | +1.04% |
DASATINIB 100 MG TABLET | $26.4568 per EA | +1.04% |
DASATINIB 100 MG TABLET | $26.4568 per EA | +1.04% |
DASATINIB 100 MG TABLET | $26.4568 per EA | +1.04% |
DASATINIB 100 MG TABLET | $26.4568 per EA | +1.04% |
DASATINIB 100 MG TABLET | $26.4568 per EA | +1.04% |
DASATINIB 100 MG TABLET | $26.4568 per EA | +1.04% |
Frequently Asked Questions
What is Dasatinib used to treat?
Dasatinib is used to treat lymphoid leukemia and myeloid leukemia, per the National Library of Medicine's MED-RT classification.
When did Dasatinib become available as a generic?
FDA approved the first generic Dasatinib (ANDA) on Jun 10, 2016. The Orange Book currently lists 54 AB-rated products for this ingredient, meaning FDA considers them therapeutically equivalent to the brand.
How much does Medicare spend on Dasatinib?
In 2024, Medicare Part D spent $569 million on Dasatinib across 44,000 claims for 7,778 beneficiaries.
How many Dasatinib products are on the market?
The Dasatinib drug market contains 10 NDCs from 9 manufacturers — 8 generic and 2 brand products.
What is the price range for Dasatinib?
NADAC reference prices for Dasatinib range from $26.4568 to $591.1812 per EA — the most expensive product costs about 22× the cheapest.
Is generic Dasatinib cheaper than brand?
The average generic NADAC for Dasatinib is $26.4568 per EA, versus $459.3025 for brand-labeled products — brand versions average about 17× the generic price.
Which manufacturers make Dasatinib?
9 manufacturers list Dasatinib in NADAC. Ranked by number of NDCs, the largest are E.R. Squibb & Sons, L.L.C. (2), Aurobindo Pharma Limited (1), Apotex Corp. (1), Prasco Laboratories (1), Teva Pharmaceuticals USA Inc. (1).
How has the price of Dasatinib changed recently?
Over the past 7 days, 8 Dasatinib NDCs rose and 0 fell, with a market-wide average change of +1.0%.